ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Neuronetics Inc

Neuronetics Inc (STIM)

2.15
-0.19
(-8.12%)
Al cierre: 14 Enero 3:00PM
2.15
0.00
( 0.00% )
Fuera de horario: 3:00PM
Gráfico avanzado

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
2.15
Postura de Compra
2.10
Postura de Venta
2.22
Volume Operado de la Acción
1,304,690
1.9601 Rango del Día 2.33
0.52 Rango de 52 semanas 5.0699
Capitalización de Mercado [m]
Precio Anterior
2.34
Precio de Apertura
2.22
Última hora de negociación
15:00:00
Volumen financiero
US$ 2,810,515
Precio Promedio Ponderado
2.1542
Volumen promedio (3 m)
619,868
Acciones en circulación
30,347,504
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.13
Beneficio por acción (BPA)
-0.99
turnover
71.35M
Beneficio neto
-30.19M

Acerca de Neuronetics Inc

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-sy... Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Neuronetics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker STIM. The last closing price for Neuronetics was US$2.34. Over the last year, Neuronetics shares have traded in a share price range of US$ 0.52 to US$ 5.0699.

Neuronetics currently has 30,347,504 shares in issue. The market capitalisation of Neuronetics is US$71.01 million. Neuronetics has a price to earnings ratio (PE ratio) of -2.13.

STIM Últimas noticias

Neuronetics Provides Business Update and Issues 2025 Guidance

Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.57936.85550604711.5712.81.40128830602.27166083CS
41.0595.45454545451.12.81.18715322.08683975CS
121.1511512.80.526198681.37563712CS
260.2814.97326203211.872.80.524954121.18059201CS
52-0.86-28.57142857143.015.06990.523296651.66210478CS
156-1.78-45.29262086513.936.930.522757032.76126811CS
260-2.07-49.05213270144.2222.430.523485965.21709948CS

STIM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Neuronetics?
El precio actual de las acciones de Neuronetics es US$ 2.15
¿Cuántas acciones de Neuronetics están en circulación?
Neuronetics tiene 30,347,504 acciones en circulación
¿Cuál es la capitalización de mercado de Neuronetics?
La capitalización de mercado de Neuronetics es USD 71.01M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Neuronetics?
Neuronetics ha negociado en un rango de US$ 0.52 a US$ 5.0699 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Neuronetics?
El ratio precio/beneficio de Neuronetics es -2.13
¿Cuál es el ratio de efectivo a ventas de Neuronetics?
El ratio de efectivo a ventas de Neuronetics es 0.9
¿Cuál es la moneda de reporte de Neuronetics?
Neuronetics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Neuronetics?
El último ingresos anual de Neuronetics es USD 71.35M
¿Cuál es el último beneficio anual de Neuronetics?
El último beneficio anual de Neuronetics es USD -30.19M
¿Cuál es la dirección registrada de Neuronetics?
La dirección registrada de Neuronetics es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Neuronetics?
La dirección del sitio web de Neuronetics es www.neurostar.com
¿En qué sector industrial opera Neuronetics?
Neuronetics opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VMARVision Marine Technologies Inc
US$ 1.90
(34.69%)
1.12M
HSDTHelius Medical Technologies Inc
US$ 0.7966
(15.12%)
33.46k
MASS908 Devices Inc
US$ 2.26
(14.43%)
21.86k
BTOGBit Origin Ltd
US$ 0.70
(11.91%)
143
UPCUniverse Pharmaceuticals Inc
US$ 0.6199
(8.75%)
703.4k
WNWMeiwu Technology Company Ltd
US$ 0.8698
(-13.02%)
1.78M
RIMEAlgorhythm Holdings Inc
US$ 0.068
(-12.93%)
1.62M
NCRANocera Inc
US$ 0.94
(-12.15%)
63.41k
XRTXXORTX Therapeutics Inc
US$ 1.1498
(-9.46%)
62.19k
GLXGGalaxy Payroll Group Ltd
US$ 1.19
(-8.34%)
10.88k
WNWMeiwu Technology Company Ltd
US$ 0.8698
(-13.02%)
1.78M
RIMEAlgorhythm Holdings Inc
US$ 0.068
(-12.93%)
1.62M
EVGOEVgo Inc
US$ 3.75
(0.27%)
1.29M
VMARVision Marine Technologies Inc
US$ 1.90
(34.69%)
1.12M
RGTIRigetti Computing Inc
US$ 8.93
(-0.11%)
1.04M

STIM Finanzas

Finanzas

STIM Discussion

Ver más
TrendTrade2016 TrendTrade2016 1 día hace
STIM WHAT A BEAUTIFUL DAYTRADE
👍️0
TrendTrade2016 TrendTrade2016 1 día hace
STIM MONSTER
👍️0
TrendTrade2016 TrendTrade2016 1 día hace
STIM ON THE MOVE
👍️0
glenn1919 glenn1919 1 día hace
STIM........................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 meses hace
STIM under $3
👍️0
Dubster watching Dubster watching 8 meses hace
Going to do it again!
👍️0
Dubster watching Dubster watching 8 meses hace
Got 6% 2 hours
👍️0
Dubster watching Dubster watching 8 meses hace
Momentum play!
👍️0
Monksdream Monksdream 10 meses hace
STIM 10Q due March 5
👍️0
Monksdream Monksdream 1 año hace
STIM new 52 week low
👍️0
Monksdream Monksdream 1 año hace
STIM new 52 week low
👍️0
AJ Freely AJ Freely 1 año hace
$STIM - 👆Up 6.8% Pre-Market/ Current Price $2.06
Reports Record Q2 '23 Financial & Operating Results
👉Q2 '23 revenue of $17.6m, an increase of 8% over the Q2 '22
👉U.S. treatment session revenue increased 9% over the Q2 of '22
👉Shipped 54 NeuroStar systems
👍️0
luckydude777 luckydude777 2 años hace
Slowly moving UP. VERY INTERESTED in their technology. In time, we may be looking at a very LUCRATIVE company here.

We'll see ...
👍️0
luckydude777 luckydude777 2 años hace
Wow - after hours filled the gap in ONE day. Very interesting ...
👍️0
luckydude777 luckydude777 2 años hace
How big of a deal do you think today's news IS?
👍️0
subslover subslover 2 años hace
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
July 19 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug-resistant depression and obsessive-compulsive disorder (OCD), announced clearance from the U.S. Food and Drug Administration (FDA) for a new indication for its transcranial magnetic stimulation (TMS) system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression.
“Today, we celebrate a big win for NeuroStar patients and providers,” said Keith J. Sullivan, President and CEO of Neuronetics Inc. “Many people suffering from MDD also experience anxiety symptoms, and these patients with anxious depression are more likely to be severely depressed and to have more thoughts of suicide. This new indication means providers can now describe to MDD patients the benefit of NeuroStar for improving their anxiety symptoms.”

NeuroStar is the leader in patient-focused TMS therapy having treated over 134,000 patients who completed more than 4.8 million treatment sessions. The FDA accepted Neuronetics’ use of real-world data analyzed from NeuroStar’s proprietary TrakStar® platform in granting clearance for this new indication. The TrakStar database contains digital data from patients treated with NeuroStar at over 1,000 centers. Real-world data from TrakStar is particularly valuable because it provides a large sample from a diverse patient group being treated in a clinical practice setting.

“We would like to acknowledge the contributions of healthcare providers across the country who have partnered with us to help build the world’s largest database of depression outcomes,” said Cory Anderson, VP R&D and Clinical. “Not only do we have MDD outcomes, but we also receive data on anxiety outcomes from patients with anxious depression, and these real-world results in anxious depression were an important piece of the FDA clearance.”

The TrakStar results from 664 anxious depression patients demonstrated that 65.5% achieved a clinically meaningful response which exceeded the pre-established overall study success criteria of a minimum 50% response rate (p<0.0001) and indicated a large treatment effect size of 1.4.

“A clinical presentation of anxiety symptoms in patients with MDD is typically more complex to successfully treat with currently available medications,” said Melissa Fickey, MD, founder of Embracing Life Wellness Center. “NeuroStar has presented a robust data set from over 1,300 patients showing safety and efficacy in relieving both depression and anxiety symptoms in patients with anxious depression.”

DASH, TouchStar™, and standard MDD protocols offered by NeuroStar are all now indicated to treat depression with comorbid anxiety. This clearance closely follows after NeuroStar’s announcement of an obsessive compulsive disorder (OCD) indication, which received FDA clearance in May of this year. For more information about NeuroStar Advanced Therapy for Mental Health, please visit neurostar.com

About Anxious Depression
Major depressive disorder (MDD) is a common and serious psychiatric diagnosis among adults with an estimated prevalence of 13.9M patients under treatment in the United States. Anxiety symptoms are a common co-morbidity in patients with MDD, commonly called anxious depression, with an estimated prevalence of more than 50% of MDD patients. The NeuroStar Advanced Therapy System is now indicated for treating anxiety symptoms for those who may exhibit comorbid anxiety and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decre
👍️0
urge2surge urge2surge 3 años hace
Guess we got a dog pile here..
👍️0
oxnous oxnous 3 años hace
UGLY day


👍️0
urge2surge urge2surge 4 años hace
Thank you I'll take a look. Yes it works. If they announce trials on Alzheimer's, who knows where this goes. As it is this is a solid growth company. I was surprised at the secondary offering in light of their revenues.
As for BWAY, the only negative off the cuff is that it is an Israeli company. Tend to be big sink holes...
👍️0
EarthBard EarthBard 4 años hace
Brains at (BWAY) is the only other company I know.

My son is an rTMS tech and tells me flat out that it works.

EB
👍️0
urge2surge urge2surge 4 años hace
This is a major winning technology an stock, and the board is dead??????
👍️0
urge2surge urge2surge 4 años hace
Looking at a solid and easy 100 dollar stock here. The treatments work!!!!
👍️0
urge2surge urge2surge 4 años hace
Are their any other public companies in this sector?
Thanks in advance
👍️0
TFMG TFMG 4 años hace
$STIM | #Neuronetics Inc +60% Potential Upside


Neuronetics , Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS , a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Average Analysts Recommendation: BUY
Average Target Price: $5.75




👍️0
wesley_ wesley_ 4 años hace
$4.64
👍️0
wesley_ wesley_ 4 años hace
$3.96
👍️0
wesley_ wesley_ 4 años hace
$3.85
👍️0
wesley_ wesley_ 4 años hace
$3.44 lovely
👍️0
ClayTrader ClayTrader 5 años hace
* * $STIM Video Chart 07-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
wesley_ wesley_ 5 años hace
creeping back up HOD for next leg up :)
👍️0
wesley_ wesley_ 5 años hace
$3+ surge lovely
👍️0
wesley_ wesley_ 5 años hace
$2.88 nice
👍️0
ClayTrader ClayTrader 5 años hace
* * $STIM Video Chart 06-23-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
instock58 instock58 5 años hace
STIM Up 18.8% , UP 2,87 In AH so far. Slowly rising. Healthcare stocks HOT today...


$STIM should have a strong Open and pre market Wednesday ...especially if price keeps rising in AH,
Closed 2.09
Current 2.16
👍️0
CA CHASE CA CHASE 5 años hace
$STIM ADDING BELOW $2.15 FOR ROUND #2 ^
👍️0
CA CHASE CA CHASE 5 años hace
$STIM BELOW $2.20 DIP & RIP END OF DAY ^
👍️0
crudeoil24 crudeoil24 5 años hace
Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock